Genelabs Technologies, Inc.

Alios Biopharma, Inc.

Smithkline Beecham Corporation

Janssen Biopharma, Inc.

Janssen Pharmaceutica Nv

Janssen Pharmaceuticals, Inc.

Natalia Dyatkina

Christopher Don Roberts

Leonid Beigelman

David Bernard Smith

Jesse Daniel Keicher

Guangyi Wang

Lawrence M Blatt

Julian Alexander Symons

Peter H Nelson

Joseph M Muchowski

Vivek Kumar Rajwanshi

Alexander Khorlin

Dong-Fang Shi

Mark Douglas Velligan

Janos Botyanszki

Wentao Zhang

Sebastian Johannes Reinhard Liehr

Jerome Deval

Marija Prhavc

Ronald Griffith

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Substituted nucleosides, nucleotides and analogs thereof

Disclosed herein are nucleosides, nucleotides and analogs thereof, pharmaceutical compositions that include one or more of nucleosides, nucleotides and analogs thereof, and methods of synthesizing the same. Also disclosed herein are methods of ameliorating and/or treating a paramyxovirus viral infection, with a nucleoside, a nucleotide and an analog thereof.

Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.

Disclosed herein are phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs and thiohosphates (including &#x3b1;-thiomonophosphates, &#x3b1;-thiodiphosphates, and &#x3b1;-thiotriphosphates), methods of synthesizing phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs and thiophosphates, and methods of treating viral infections such as HCV, with the phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs and thiophosphates.

Substituted nucleotide analogs

Disclosed herein are phosphorothioate nucleotide analogs, such as thiophosphoroamidate prodrugs and thiophosphates (including &#x3b1;-thiomonophosphates, &#x3b1;-thiodiphosphates, and &#x3b1;-thiotriphosphates), methods of synthesizing phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates and methods of treating viral infections, such as HCV, cancer, and/or parasitic diseases with the phosphorothioate nucleotide analogs, such as thiophosphoramidate prodrugs, and thiophosphates.

Disclosed are &#x3b2;-D-ribofuranosyl-pyrazolo[3,4-d]pyrimidine compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Representative compounds include those having the general formula. 

Nucleoside derivatives for treating hepatitis C virus infection

Disclosed are methods for treating hepatitis C viral infections using deaza-purine compounds of Formula I: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula I as follows: wherein W, W, W, Y, R, Z, Y' and R are as defined herein.

Nucleoside derivatives for treating Hepatitis C virus infection

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus. Such compounds are represented by Formula IB as follows: and pharmaceutically acceptable prodrugs and salts thereof, where R, R, R, R, W, W, W, Y and Z are as defined herein.

Disclosed are compounds, compositions and methods for treating viral infections caused by a flaviviridae family virus, such as hepatitis C virus.

Growing community of inventors

Mountain View, CA, United States of America

Natalia Dyatkina